相关实验视频
Updated: Sep 13, 2025
11:10
Expression, Purification, and Antimicrobial Activity of S100A12
Published on: May 13, 2017
8.5K
针对S100A9介导的炎症:一种新的治疗方法来治疗CLL
Angimar Uriepero-Palma1, Maria Elena Marquez2, Eugenia Payque3
1H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States.
Blood advances
|July 28, 2025
概括
慢性淋巴细胞白血病 (CLL) 涉及炎症和免疫功能障碍. 准促炎蛋白S100A9显示出通过调节免疫反应来治疗CLL的前景.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 由于耐药性和复发,在治疗中表现出挑战.
- 慢性炎症和免疫功能障碍是CLL病变的关键因素.
- 促炎性蛋白质S100A9与各种癌症和自身免疫性疾病有关.
研究的目的:
- 研究S100A9在CLL进展中的作用.
- 阐明S100A9在CLL中的功能背后的分子机制.
- 评估S100A9作为CLL的潜在治疗点.
主要方法:
- 对由CLL患者释放的外体的分析.
- 使用体内小鼠模型 (Eμ-TCL1 和 Eμ-TCL1/S100A9-/-).
- 使用患者衍生异种移植 (PDX) 模型进行药理向.
主要成果:
- 患有CLL的患者释放含有S100A9的外体,与NF-κB激活相关.
- 在CLL中发现了一种新的S100A9/EMMPRIN相互作用机制.
- 在临床前模型中,S100A9的药理向证明了治疗潜力.
结论:
- S100A9在CLL进展和免疫调节中发挥着重要作用.
- S100A9/EMMPRIN轴代表了CLL的一个新的治疗点.
- 向S100A9具有临床应用在CLL治疗中的潜力.
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
235
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
235